3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
12
Carcinoma, Medullary
9
Lung Neoplasms
8
Thyroid Neoplasms
7
Neoplasms
5
Neoplasm Metastasis
5
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Stomach Neoplasms
2
Pleural Effusion
2
Kidney Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Familial medullary thyroid carcinoma
2
Fallopian Tube Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid cancer, medullary
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Small Cell Lung Carcinoma
1
Recurrence
1
Rectal Neoplasms
1
Precancerous Conditions
1
Peritoneal Neoplasms
1
Oligodendroglioma
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Interventions
3-Iodobenzylguanidine
3
cabozantinib
2
pembrolizumab
1
pazopanib
1
lutetium Lu 177 dotatate
1
guadecitabine
1
gallium Ga 68 dotatate
1
copper dotatate CU-64
1
atezolizumab
1
Sunitinib
1
Radiosurgery
1
Phenoxybenzamine
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Iodine-131
1
Everolimus
1
Erlotinib Hydrochloride
1
Doxazosin
1
Axitinib
1
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Paraganglioma
×
vandetanib
×
Clear all
No trials found.